Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25420978 | 1.00 | MTNR1A (0.37) | MTNR1AMTNR1BDGAT1PDE10AMAPT | |
| SCHEMBL20455667 | 0.85 | DGAT1 (0.38) | DGAT1PDE10AMAPTNPC1 | |
| SCHEMBL29659291 | 0.85 | DGAT1 (0.38) | DGAT1PDE10AMAPTNPC1 | |
| SCHEMBL25345695 | 0.85 | DGAT1 (0.41) | DGAT1PDE10AMAPTNPC1 | |
| SCHEMBL29513596 | 0.85 | DGAT1 (0.41) | DGAT1PDE10AMAPTNPC1 | |
| SCHEMBL29513573 | 0.82 | DGAT1 (0.36) | DGAT1PDE10AMAPTNPC1 | |
| SCHEMBL25345296 | 0.82 | DGAT1 (0.36) | DGAT1PDE10AMAPTNPC1 | |
| SCHEMBL25420967 | 0.81 | DGAT1 (0.43) | DGAT1PDE10AMAPT | |
| SCHEMBL30461686 | 0.81 | DGAT1 (0.43) | DGAT1PDE10AMAPT | |
| SCHEMBL31512683 | 0.81 | DGAT1 (0.38) | MTNR1AMTNR1BDGAT1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099442-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES INC | 2025-03-27 | — | — | US | disclosed |
| EP-4444721-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107722-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099442-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | DYRK2, DYRK1A, DYRK1B | MTNR1A 592/4885MTNR1B 755/4885DGAT1 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.